DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis Reduction
Top-line results from the OPTIC trial showed that the phase 3 study met its primary endpoint, demonstrating that more patients with active thyroid eye disease assigned teprotumumab experienced a meaningful improvement in proptosis, or protrusion of the eyeball, compared with patients assigned placebo, according to a press release from Horizon Pharma.
In the study, designed to investigate the efficacy, tolerability and safety of teprotumumab in patients with active thyroid eye disease, researchers assigned 83 patients to teprotumumab or placebo in eight IV infusions (10 mg/kg for the first infusion followed by 20 mg/kg for the remaining seven infusions) every 3 weeks for 21 weeks, according to the release. The primary endpoint was a 2 mm or more reduction of proptosis in the study eye, without deterioration in the fellow eye, at week 24. Proptosis is the main cause of morbidity in thyroid eye disease.


Related Content
-
People & PlacesBarbra Sue Miller, MDBarbra S. Miller is the Co-Director of T...
-
Evidence & EducationRisk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
-
People & PlacesTerry Jay Smith, MDDr. Terry J. Smith, the Frederick G.L. H...
-
People & PlacesDouglas S. Ross, MDDouglas S. Ross is a Co-director of Thyr...
-
Evidence & EducationRelation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
People & PlacesUniversity of Miami Health SystemWe leverage the latest research complete...
-
Evidence & EducationTreatment of Hyperthyroidism With Antithyroid Drugs Corrects Mild Neutropenia in Graves’ DiseaseContext: Neutropenia secondary to antit...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.